LEXICON
No.155 March 9, 2018

New PMP Criteria
新薬創出加算の新要件

The price maintenance premium (PMP) (新薬創出加算; shinyaku soshutsu kasan ) , which has been in place since its pilot rollout in April 2010, has been hailed by the research-oriented pharmaceutical industry as the centerpiece of Japan’s pro-innovation policy. While it...

To read the full story

LEXICON

By Reiji Anasako

Kyowa Hakko Kirin’s first and only Rituxan (rituximab) biosimilar in Japan is showing a faster-than-expected uptake in the market, with the company racking up 4.3 billion yen from the cancer drug in 2018, far beyond its initial 3.2 billion yen…

Members of a key reimbursement policy panel appear to be becoming more and more open to the industry’s call for…

By Takashi Ebisawa

A series of drug makers restructured or sold off production facilities in FY2018. Others dissolved or withdrew from the pharmaceutical business altogether. The entry of generics and transfer of products triggered these moves, but the underlying factor was the impact…

By Philip Carrigan

With a cursory glance, recruitment is easily defined. We’re here to help place candidates into the vacancies our clients need to fill. Armed with a pen and paper, you could even map out the process.• We study the market• We…